Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Logan, Brent  [Clear All Filters]
2024
Grunebaum E, Arnold DE, Logan B, Parikh S, Marsh RA, Griffith LM, Mallhi K, Chellapandian D, Lim SSi, Deal CL, et al. Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: a PIDTC study. J Allergy Clin Immunol. 2024.
Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, et al. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. J Clin Oncol. 2024:JCO2300934.
2023
Cho C, Devlin S, Maloy M, Horowitz MM, Logan B, J Rizzo D, Giralt SA, Perales M-A. Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis. Bone Marrow Transplant. 2023.
Jurdi NEl, Martens MJ, Brunstein CG, O'Donnell P, Lee SJ, D'Souza A, Logan B, Hong S, Singh AK, Sandhu K, et al. Heath-related Quality of Life in Double Umbilical Cord Blood vs. Haploidentical Marrow Transplantation: a QOL Analysis Report of BMT CTN 1101. Transplant Cell Ther. 2023.
Sharma A, Logan B, Estrada-Merly N, Lehmann LE, Rangarajan HG, Preussler JM, Troy JD, Akard LP, Bhatt NS, Truong TH, et al. Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers. Transplant Cell Ther. 2023.
Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, et al. Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma. Clin Cancer Res. 2023.
2022
Farhadfar N, Ahn KWoo, Bo-Subait S, Logan B, Stefanski H, Hsu JW, Panch S, Confer D, Liu H, Badawy SM, et al. The impact of pre-apheresis Health Related Quality of Life on peripheral blood progenitor cell yield and donor's health and outcome: Secondary analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. Transplant Cell Ther. 2022.
2021
Panch SR, Logan B, Sees JA, Bo-Subait S, Savani B, Shah NN, Hsu JW, Switzer G, Lazarus HM, Anderlini P, et al. Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. Transplant Cell Ther. 2021.
2019
Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, et al. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol. 2019.
Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, et al. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Biol Blood Marrow Transplant. 2019.